Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:RIVNASDAQ:TERN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRIVRiverNorth Opportunities Fund$12.07+0.3%$11.52$10.11▼$12.96N/AN/A76,079 shs43,370 shsTERNTerns Pharmaceuticals$3.55+1.0%$2.81$1.87▼$11.40$309.61M-0.181.52 million shs481,891 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRIVRiverNorth Opportunities Fund-0.50%+0.92%+2.81%-0.82%-1.23%TERNTerns Pharmaceuticals+0.57%+14.71%+6.36%-3.31%-40.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationRIVRiverNorth Opportunities FundN/AN/AN/AN/AN/AN/AN/AN/ATERNTerns Pharmaceuticals3.9066 of 5 stars3.31.00.04.12.92.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceRIVRiverNorth Opportunities Fund 0.00N/AN/AN/ATERNTerns Pharmaceuticals 2.60Moderate Buy$15.63340.76% UpsideCurrent Analyst Ratings BreakdownLatest TERN, LGT, RIV, and ESO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025TERNTerns PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$26.00 ➝ $15.004/21/2025TERNTerns PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.003/21/2025TERNTerns PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookRIVRiverNorth Opportunities Fund$44.13MN/AN/AN/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/A$4.13 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateRIVRiverNorth Opportunities FundN/AN/A0.00∞N/AN/AN/AN/AN/ATERNTerns Pharmaceuticals-$90.21M-$1.09N/AN/AN/AN/A-32.76%-31.33%8/4/2025 (Estimated)Latest TERN, LGT, RIV, and ESO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025TERNTerns Pharmaceuticals-$0.29-$0.26+$0.03-$0.26N/AN/A3/20/2025Q4 2024TERNTerns Pharmaceuticals-$0.30-$0.24+$0.06-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthRIVRiverNorth Opportunities Fund$1.6613.75%-8.84%N/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/AN/ALatest TERN, LGT, RIV, and ESO DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/4/2025RIVRiverNorth Opportunities Fundmonthly$0.127713%6/13/20256/13/20256/30/20254/3/2025RIVRiverNorth Opportunities Fundmonthly$0.127713%6/13/20256/13/20256/30/20255/13/2025RIVRiverNorth Opportunities Fund$0.127712.72%5/15/20255/16/20255/30/20254/9/2025RIVRiverNorth Opportunities Fund$0.127714.71%4/15/20254/16/20254/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioRIVRiverNorth Opportunities FundN/AN/AN/ATERNTerns PharmaceuticalsN/A32.9932.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipRIVRiverNorth Opportunities FundN/ATERNTerns Pharmaceuticals98.26%Insider OwnershipCompanyInsider OwnershipRIVRiverNorth Opportunities FundN/ATERNTerns Pharmaceuticals1.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableRIVRiverNorth Opportunities FundN/AN/AN/ANot OptionableTERNTerns Pharmaceuticals4087.34 million72.11 millionNot OptionableTERN, LGT, RIV, and ESO HeadlinesRecent News About These CompaniesVoloridge Investment Management LLC Sells 98,066 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 31, 2025 | marketbeat.comTerns Pharmaceuticals to Participate in Upcoming June Investor ConferencesMay 29, 2025 | globenewswire.comInfinitum Asset Management LLC Takes $1.11 Million Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 28, 2025 | marketbeat.comTerns Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potentialMay 27, 2025 | investing.comNuveen Asset Management LLC Buys 617,009 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 27, 2025 | marketbeat.comNorthern Trust Corp Has $3.28 Million Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 26, 2025 | marketbeat.comDeutsche Bank AG Has $2.21 Million Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 25, 2025 | marketbeat.comVR Adviser LLC Sells 2,332,968 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 22, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Position Cut by Point72 Asset Management L.P.May 22, 2025 | marketbeat.comCubist Systematic Strategies LLC Decreases Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 22, 2025 | marketbeat.comBNP Paribas Financial Markets Acquires New Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 22, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) is Soleus Capital Management L.P.'s 10th Largest PositionMay 21, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Bought by Graham Capital Management L.P.May 17, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Bought by Parkman Healthcare Partners LLCMay 16, 2025 | marketbeat.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 16, 2025 | marketbeat.comTerns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701May 14, 2025 | globenewswire.comTerns Pharmaceuticals (NASDAQ:TERN) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPSMay 14, 2025 | marketbeat.comIntegral Health Asset Management LLC Increases Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 14, 2025 | marketbeat.comDimensional Fund Advisors LP Raises Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 13, 2025 | marketbeat.comDriehaus Capital Management LLC Decreases Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 12, 2025 | marketbeat.comWhy Terns Pharmaceuticals, Inc.’s (TERN) Stock Is Up 11.67%May 10, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueQuantum Stocks Skyrocket, Led by IonQ's NVIDIA DeclarationBy Leo Miller | May 27, 2025View Quantum Stocks Skyrocket, Led by IonQ's NVIDIA DeclarationBuybacks and Big-Time Developments: 3 Stocks Making Huge MovesBy Leo Miller | May 19, 2025View Buybacks and Big-Time Developments: 3 Stocks Making Huge MovesTesla: Why Analysts Think It Could Jump Another 47%By Sam Quirke | May 27, 2025View Tesla: Why Analysts Think It Could Jump Another 47%BigBear.ai: Risky AI Stock or Defense Tech Opportunity?By Jeffrey Neal Johnson | May 28, 2025View BigBear.ai: Risky AI Stock or Defense Tech Opportunity?TERN, LGT, RIV, and ESO Company DescriptionsRiverNorth Opportunities Fund NYSE:RIV$12.07 +0.04 (+0.33%) Closing price 03:59 PM EasternExtended Trading$12.12 +0.05 (+0.41%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RiverNorth Opportunities Fund, Inc. is a close ended equity mutual fund co- launched and co- managed by ALPS Advisors, Inc. and RiverNorth Capital Management, LLC. It invests in the equity markets. The fund seeks to invest in stocks of companies operating across the diversified sectors. RiverNorth Opportunities Fund, Inc. was formed on December 24, 2015 and is domiciled in the United States.Terns Pharmaceuticals NASDAQ:TERN$3.54 +0.04 (+1.00%) Closing price 03:59 PM EasternExtended Trading$3.54 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Guidewire Rockets Higher: A Move Above $300 Is Probable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
